Tasly Pharmaceutical Group Co., Ltd
Clinical trials sponsored by Tasly Pharmaceutical Group Co., Ltd, explained in plain language.
A Chinese pharmaceutical company known for traditional Chinese medicine and modern drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New depression pill JS1-1-01 enters key trials Results expected Dec 2026 (estimated)
- New pill shows promise against resistant cancers in early trial Results expected Dec 2026 (estimated)
- Could umbilical cord stem cells help failing hearts? Results expected Dec 2026 (estimated)
- Herbal granules aim to ease Post-Meal stomach troubles Results expected Dec 2026 (estimated)
-
Could herbal pills cut eye injections for wet AMD? new trial launches
Disease control Not yet recruitingThis phase 3 trial tests whether adding Sanhuang Jingshiming Pills (a traditional Chinese herbal medicine) to standard ranibizumab injections can reduce the number of injections needed for wet age-related macular degeneration. About 450 adults aged 50-85 with active wet AMD will …
Phase 3 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New depression pill JS1-1-01 enters key trials
Symptom relief Not yet recruitingThis study tests an experimental tablet called JS1-1-01 in 180 adults with moderate to severe depression. Participants will take either a low dose, high dose, or placebo for 8 weeks. The goal is to see if the drug safely reduces depression symptoms better than a placebo.
Phase 2/3 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC